Enterome and Nestlé Health Science to work on food allergies and IBD

Enterome, a clinical-stage biopharmaceutical company developing immunomodulatory drugs based on its Mimiry bacterial drug discovery platform, has signed a strategic R&D collaboration and license agreement with Nestlé Health Science targeting food allergies and inflammatory bowel disease (IBD). .

The collaboration aims to develop and commercialize Enterome EndoMimics’ lead pipeline candidate EB1010. EB1010 is a topical IL-10 inducer designed to provide improved therapeutic outcomes for patients with food allergy and IBD. EB1010, which will enter clinical trials in 2023, was discovered using Enterome’s bacterial Mimicry drug discovery platform. The same platform will also be used to identify and develop novel EndoMimics as potential new therapies for inflammation associated with food allergies.

The companies also hope to identify and develop a new line of AllerMimics (allergen immunotherapies for food allergies) using Enterome’s Mimiry platform with an initial focus on peanut allergens as the basis for a new class of immunotherapies aimed at suppressing allergic reactions.

Details of the agreement

Under the terms of the agreement, Enterome will receive 40 million euros ($40.5 million) in cash and equity from Nestlé Health Science and is also entitled to receive clinical and sales payments for each licensed therapeutic candidate plus royalties on sales net. Enterome will be responsible for leading drug discovery activities and will bear the associated costs up to the investigational new drug (IND) application.

“We will generate new AllerMimics candidates using our highly productive Mimicry drug discovery platform, which has already allowed us to discover many first-in-class protein and small peptide candidates in a wide range of therapeutic areas. AllerMimics are a truly novel class of specific antigens produced by the microbiome that are similar to food allergens and function by helping the body’s immune system tolerate these specific allergens,” said Christophe Bonny, Enterome’s Chief Scientific Officer.

“The collaboration will also allow us to advance the clinical development of EB1010, the first candidate originating from our EndoMimicsTM line. We believe that EB1010, administered orally as a pill, has the potential to prevent or reduce the intensity of allergic reactions in the gut. EB1010, which will also be evaluated in inflammatory bowel disease, will be applicable to many different types of food allergy, potentially in combination with select AllerMimics.

Hans-Juergen Woerle, chief scientific and medical officer of Nestlé Health Science said: “Approximately 220 million people worldwide live with food allergies, while seven million live with inflammatory bowel disease. Through this collaboration, we are aiming to develop new therapies for these two disease areas with high unmet medical needs. We are excited about the opportunity to partner with Enterome on their unique microbiome drug discovery platform, striving to develop first-in-class, high-quality treatment solutions that will help patients lead a life healthier.”

New therapeutics

“We are excited to sign this R&D agreement to develop a new pipeline of new AllerMimics candidates, as well as to further develop and commercialize EB1010, our lead EndoMimics candidate, with Nestlé Health Science, a world leader in food allergies,” said Pierre Belichard, CEO. of Enteroma.

“The signing of this collaboration further highlights both the potential and the growing interest in our Mimiry platform as a source of novel immunotherapies. This milestone is even more exciting following the recent clinical and immunological validation of the mode of action of EO2401, our first-in-class immunotherapy of OncoMimics for glioblastoma and adrenal carcinoma.

Enterome’s Mimiry drug discovery platform is based on its ability to decipher the interaction between the gut microbiome and the immune system. The Mimicry platform uses biocomputational tools and bioassays to identify novel therapies for a wide range of indications from a proprietary database of more than 20 million full-length gut microbiome peptides and proteins.

Leave a Comment

Your email address will not be published.